Biotechnology Analyst Ritu Baral Joins Cowen’s Equity Research Department

Cowen Group, Inc. (“Cowen”) (NASDAQ:COWN) today announced that Ritu Baral has joined Cowen and Company’s Equity Research department as a Managing Director to cover Biotechnology stocks. Ms. Baral is based in New York and reports to Robert Fagin, Cowen’s Director of Research.

“Investors appreciate Ritu’s thoughtful research product and insight,” said Mr. Fagin. “We are excited to add her respected voice to our biotechnology research platform, and look forward to her collaboration with the rest of our health care team.”

Ms. Baral joins Cowen from Canaccord Genuity, where she spent seven years focused on the biotechnology sector. She holds a Bachelor of Arts degree in Biological Sciences from Barnard College.

About Cowen Group, Inc.

Cowen Group, Inc. is a diversified financial services firm and, together with its consolidated subsidiaries, provides alternative asset management, investment banking, research, and sales and trading services through its two business segments: Ramius and its affiliates make up the Company’s alternative investment segment, while Cowen and Company and its affiliates make up the Company’s broker-dealer segment. Ramius provides alternative asset management solutions to a global client base and manages a significant portion of Cowen’s proprietary capital. Cowen and Company and its affiliates offer industry focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Founded in 1918, the firm is headquartered in New York and has offices worldwide.